Skip to main content

Dyadic Raises $3M from Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dyadic International today announced it has raised $3 million from a completed private placement with two unnamed investors.

The proceeds will be used for working capital, including for R&D, and general corporate purposes, the Jupiter, Fla., company said in a statement.

The notes, which will pay interest quarterly at a rate of 8 percent annually, are convertible at the holder's option after Jan. 1, 2011 into shares of Dyadic's common stock. The conversion price is $1.82, 120 percent of the company's average share price for the 30 days prior to the closing date. The notes mature on Jan. 1, 2013.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.